While others may be ahead, I-O is 'marathon, not sprint', says Regeneron oncology head

At an unusually quiet annual meeting of the American Society of Clinical Oncology, Joanne Lager and Israel Lowy, the oncology heads of Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN), found time to speak with The Pharma Letter to discuss progress in their long-standing collaboration.

In a 2015 renewal of the oncology accord, Sanofi ploughed $640 million into the collaboration and committed to potential sales milestone of $375 million.

The companies have been jointly advancing PD-1 and other new immuno-oncology antibodies, including REGN2810, a compound being explored as a monotherapy for multiple cancers, as well as in combination with REGN3767, another of their investigational immunotherapies, which targets the LAG-3 checkpoint inhibitor.